| Isentress (raltegravir) / Merck (MSD) |
NCT00782301: Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients |
|
|
| Withdrawn | 4 | 0 | US, Canada, Europe | maraviroc, Selzentry, etravirine | ViiV Healthcare, Pfizer | Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic | 02/10 | 02/10 | | |
NCT01529749 / 2011-002071-42: Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated |
|
|
| Completed | 4 | 48 | Europe | EFV/FTC/TDF + Losartan, EFV/FTC/TDF, FTC/TDF + MK-0518, FTC/TDF+MK-0518+Losartan | Felipe Garcia | HIV-1 Infection | 03/12 | 02/16 | | |
| Withdrawn | 4 | 0 | Europe | raltegravir, Atazanavir/ritonavir | University Hospital, Bonn, Dr. Axel Baumgarten, Berlin, Dr. Christoph Stephan, Frankfurt/M, Dr. Stefan Esser, Essen, Dr. Keikawus Arastéh, Berlin, Prof. Dr. Hans-Jürgen Stellbrink, Hamburg, Dr. Thomas Lutz, Frankfurt/M, Dr. Jörg Gölz , Berlin | HIV, Hepatitis C | 08/12 | 08/12 | | |
NCT01105611 / 2010-018326-39: Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users |
|
|
| Unknown status | 4 | 40 | Europe | Raltegravir, Isentress™, Atazanavir/Ritonavir, Reyataz™ (Atazanavir), Norvir™ (Ritonavir) | St. James's Hospital, Ireland | HIV Infections, Hepatitis C | 12/12 | 12/12 | | |
NCT00843713: Effect of Raltegravir on Endothelial Function in HIV-Infected Patients |
|
|
| Completed | 4 | 56 | US | raltegravir, Placebo | University of California, San Francisco, National Heart, Lung, and Blood Institute (NHLBI), Merck Sharp & Dohme LLC | HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections | 11/13 | 02/14 | | |
| Unknown status | 4 | 24 | Europe | raltegravir, Isentress | UMC Utrecht, Merck Sharp & Dohme LLC | HIV Infection, Endothelial Dysfunction | 10/14 | 12/14 | | |
NCT01285050: Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds |
|
|
| Completed | 4 | 20 | US | Antiretroviral therapy (ART), raltegravir, Isentress, Emtricitabine and tenofovir disoproxil fumarate, Truvada | Johns Hopkins University, National Institute on Drug Abuse (NIDA) | HIV Infection, Hepatitis C | 04/15 | 04/15 | | |
NCT01147107: Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection |
|
|
| Completed | 4 | 80 | RoW | Raltegravir, Isentress, Efavirenz, Sustiva | University of Hawaii, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, Viet Tiep General Hospital, Hai Phong, Vietnam, Oxford University Clinical Research Unit, Vietnam | Hepatitis C, Chronic, HIV Infection | 06/16 | 06/21 | | |
NCT02577042 / 2015-002682-30: Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen |
|
|
| Completed | 4 | 42 | Europe | Raltegravir, PI-based regimen, Atorvastatin | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Aging-related Inflammation in HIV-infected Patients | 06/18 | 06/18 | | |
NCT02691065: Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection |
|
|
| Completed | 4 | 6 | Canada | Integrase Inhibitor | McGill University Health Centre/Research Institute of the McGill University Health Centre, Merck Sharp & Dohme LLC | HIV | 03/21 | 03/21 | | |
